Good-To The Moon - Tiger Brokers Online Investing Community

Like
Comment
Favorite

Superstar_L
2021-07-30

Good

Pfizer raises estimates for 2021 sales of COVID-19 vaccine to $33.5 bln

July 28 (Reuters) - Pfizer Inc on Wednesday raised its forecast for sales of the COVID-19 vaccine th

Pfizer raises estimates for 2021 sales of COVID-19 vaccine to $33.5 bln

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":808483823,"tweetId":"808483823","gmtCreate":1627606068162,"gmtModify":1703493169529,"author":{"id":4088667593285600,"idStr":"4088667593285600","authorId":4088667593285600,"authorIdStr":"4088667593285600","name":"Superstar_L","avatar":"https://static.tigerbbs.com/3623c474881053dd2ee9f883cfef3c88","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Good&nbsp;</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/808483823","repostId":2154925597,"repostType":4,"repost":{"id":"2154925597","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627469583,"share":"https://www.laohu8.com/m/news/2154925597?lang=&edition=full","pubTime":"2021-07-28 18:53","market":"us","language":"en","title":"Pfizer raises estimates for 2021 sales of COVID-19 vaccine to $33.5 bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2154925597","media":"Reuters","summary":"July 28 (Reuters) - Pfizer Inc on Wednesday raised its forecast for sales of the COVID-19 vaccine th","content":"<p>July 28 (Reuters) - Pfizer Inc on Wednesday raised its forecast for sales of the COVID-19 vaccine that it developed with Germany's BioNTech&nbsp;by 28.8% to $33.5 billion, as countries scramble to secure supply of the shots.</p>\n<p>The company said the raised sales forecast of the vaccine is based on signed deals for 2.1 billion doses this year.</p>\n<p>The drugmaker's previous forecast in May of $26 billion was based on deals signed for 1.6 billion doses. Wall Street analysts were broadly in line with that forecast at $28.51 billion, according to nine analysts polled by Refinitiv.</p>\n<p>Since then, Pfizer has said it expects to produce as much as 3 billion doses this year.</p>\n<p>Expenses and profit from the vaccine are split 50-50 between Pfizer and BioNTech.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer raises estimates for 2021 sales of COVID-19 vaccine to $33.5 bln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer raises estimates for 2021 sales of COVID-19 vaccine to $33.5 bln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-28 18:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>July 28 (Reuters) - Pfizer Inc on Wednesday raised its forecast for sales of the COVID-19 vaccine that it developed with Germany's BioNTech&nbsp;by 28.8% to $33.5 billion, as countries scramble to secure supply of the shots.</p>\n<p>The company said the raised sales forecast of the vaccine is based on signed deals for 2.1 billion doses this year.</p>\n<p>The drugmaker's previous forecast in May of $26 billion was based on deals signed for 1.6 billion doses. Wall Street analysts were broadly in line with that forecast at $28.51 billion, according to nine analysts polled by Refinitiv.</p>\n<p>Since then, Pfizer has said it expects to produce as much as 3 billion doses this year.</p>\n<p>Expenses and profit from the vaccine are split 50-50 between Pfizer and BioNTech.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154925597","content_text":"July 28 (Reuters) - Pfizer Inc on Wednesday raised its forecast for sales of the COVID-19 vaccine that it developed with Germany's BioNTech by 28.8% to $33.5 billion, as countries scramble to secure supply of the shots.\nThe company said the raised sales forecast of the vaccine is based on signed deals for 2.1 billion doses this year.\nThe drugmaker's previous forecast in May of $26 billion was based on deals signed for 1.6 billion doses. Wall Street analysts were broadly in line with that forecast at $28.51 billion, according to nine analysts polled by Refinitiv.\nSince then, Pfizer has said it expects to produce as much as 3 billion doses this year.\nExpenses and profit from the vaccine are split 50-50 between Pfizer and BioNTech.","news_type":1},"isVote":1,"tweetType":1,"viewCount":262,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}